Recently Featured

ASGCT 2026: AI-Optimized Cas12l Gene Editor Offers Compact Cas9 Alternative

June 5, 2026
BOSTON — In a potentially significant advance for the genome editing field, researchers from the biotechnology company Caszyme and the Vilnius University Institute of Biotechnology in Lithuania have developed a potent and compact variant of Cas12l nuclease. Giedrius Gasiūnas, PhD, Caszyme co-founder and CEO, presented highlights of the research at ASGCT. The work represents “a…

India’s pharma industry is going global. But can it catch up to China?

June 5, 2026
A record Sun Pharma acquisition signals global ambitions. However, significant infrastructure, capital, and policy gaps could hinder India’s aspirations to become a leading R&D powerhouse. The recent acquisition underscores the growing intent of Indian pharmaceutical companies to expand their footprint internationally, particularly as they seek to compete with established players in China. China has rapidly…

ASGCT 2026: Rare Instance of AAV Integration into Human Genome Linked to Brain Tumor

June 5, 2026
BOSTON — A team at Children’s Hospital of Philadelphia (CHOP) led by Rebecca Ahrens-Niklas, MD, PhD, and Lindsey George, MD, has described a case of a brain tumor linked to a rare integration of adeno-associated virus (AAV). George presented the work at the American Society of Gene and Cell Therapy (ASGCT) conference in a plenary…

ECO 2026: Tirzepatide Shows Potential for T1D Treatment

June 4, 2026
During ECO 2026, a pivotal study was presented that highlights the potential of tirzepatide, a dual GIP and GLP-1 agonist, in the treatment of type 1 diabetes (T1D). This research marks a significant advancement in diabetes management, as tirzepatide has primarily been explored in the context of type 2 diabetes. The findings suggest that this…

Ongoing Cases